Table 7. Exploratory cost-utility analysis

	Venetoclax with azacitidine	FLAG-Ida
Relapsed AML utility value	0.628	0.628
Median OS (months)	8.9	10.2
Adverse events utility decrement	0.018	0.014
Total QALYs	0.448	0.520
Incremental QALYs	-0.072	
Incremental cost	¶¶	
ICER	¶¶	
ICER with severity multiplier (1.7)	¶¶	

AML: acute myeloid leukaemia; ICER: incremental cost-effectiveness ratio; OS: overall survival QALY: quality-adjusted life-year;
¶¶ commercial in confidence data removed